Pharmacology Nandrolone decanoate
Pharmacological effects - antitumour, androgenic, anabolic and anesthetic. It binds to specific receptor proteins on the cell surface of target organisms and forms a receptor-nandrolon complex, which provides transport of the latter through the cell membrane to hyaloplasm, from where it diffuses through the nuclear membrane to the cell nucleus and causes the activation of gene regulators. Androgenic properties include stimulating the synthesis of nucleic acids (DNA, RNA), structural proteins, strengthening tissue respiration and oxidative phosphorylation in skeletal muscles with the accumulation of macroelements (ATP, creatine phosphate); increasing muscle mass and reducing fat tissue.
Accelerates the growth of the male genitalia and the formation of secondary sexual signs by male type. Promotes calcification of growth zones in bones and stops skeleton growth. Stimulates the secretory activity of androgen-dependent glands - male genitals (activation of the spermatogenesis process), sebaceous glands; in large doses it causes cell suppression in Leidig and reduces the synthesis of endogenous sex hormones by inhibiting the production of FSH and LH pituitary glands (negative feedback). The anabolic effect is manifested by activation of reparative processes in epithelium (cover and glandular), bone and muscle tissues as a result of stimulation of protein synthesis and structural components of cells. Increases the full absorption of amino acids from the small intestine (against a protein-rich diet), creating a positive nitrogen balance.
It stimulates the production of erythropoietin and activates anabolic processes in the bone marrow, which, when administered at the same time as iron preparations, has an anti-anemic effect. It disrupts the synthesis of vitamin K-dependent plasma coagulation factors (II, VII, IX, X) in the liver, changes the lipid profile of plasma (increases LDL concentration and decreases LDL content), enhances reabsorption of sodium and water in the kidneys, contributing to peripheral edema formation. After a 100 mg injection, Cmax is created after 1-3 weeks. It undergoes biotransformation in the liver with the formation of 17 ketosteroids. It is mainly excreted in the urine (over 90%) and about 6% in faeces.
Use of the substance Nandrolon Decanoate
Diabetic retinopathy; progressive muscle dystrophy; Verdnig-Hoffmann syndrome; conditions characterized by a negative balance of Ca2+ (senile and postclimactic osteoporosis, prolonged glucocorticoid therapy); increased catabolic processes that deplete the body's resources (chronic infectious diseases, severe injuries, extensive surgical interventions, steroid myopathy); anemia in chronic renal insufficiency, myelofibrosis, myeloid bone marrow aplasia (refractory to conventional therapy), bone marrow lesions with malignant tumour metastases, myelotoxic drugs and heavy metal salts; inoperable (with metastases) breast carcinoma in women in the post-menopausal period or after an ovarioectomy; growth retardation in children due to a lack of somatotropic hormone.
Contraindications Nandrolone decanoate
Hypersensitivity, prostate cancer, malignant breast tumours in men, breast carcinoma in women with hypercalcemia (can activate osteoclasts and cause bone resorption), pregnancy (has embryotoxicity, fetotoxicity, can cause musculinisation of the female fetus), acute and chronic liver diseases, etc. including alcohol lesions; jade, nephrotic syndrome, breastfeeding.
Restrictions on use Nandrolon deanoat
CHD, heart failure and other conditions accompanied by oedema syndrome; severe atherosclerosis, myocardial infarction (including history), arterial hypertension, cerebral circulation disorders, chronic renal failure, epilepsy, migraine, diabetes mellitus, benign prostate hyperplasia, children (up to 2 years) and elderly.